Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.363
+0.010 (2.89%)
At close: Dec 20, 2024, 4:00 PM
0.372
+0.009 (2.56%)
After-hours: Dec 20, 2024, 5:46 PM EST
Relmada Therapeutics Employees
Relmada Therapeutics had 20 employees as of December 31, 2023. The number of employees increased by 6 or 42.86% compared to the previous year.
Employees
20
Change (1Y)
6
Growth (1Y)
42.86%
Revenue / Employee
n/a
Profits / Employee
-$4,324,369
Market Cap
10.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
China Jo-Jo Drugstores | 1,003 |
Zhongchao | 142 |
Lyra Therapeutics | 88 |
Turnstone Biologics | 80 |
BiomX | 71 |
Apollomics | 45 |
Sensei Biotherapeutics | 28 |
Talphera | 15 |
RLMD News
- 12 days ago - Relmada discontinues late-stage trials for depression drug, explores sale - Reuters
- 12 days ago - Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 - GlobeNewsWire
- 17 days ago - Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why - Benzinga
- 17 days ago - Relmada's depression drug unlikely to meet main trial goal, analysis shows - Reuters
- 17 days ago - Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance - GlobeNewsWire
- 4 weeks ago - Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - GlobeNewsWire
- 5 weeks ago - Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease - GlobeNewsWire
- 5 weeks ago - Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript - Seeking Alpha